000165293 001__ 165293
000165293 005__ 20251219174252.0
000165293 0247_ $$2doi$$a10.1016/j.brachy.2022.01.006
000165293 0248_ $$2sideral$$a146971
000165293 037__ $$aART-2022-146971
000165293 041__ $$aeng
000165293 100__ $$0(orcid)0000-0002-1530-5662$$aLozares-Cordero, Sergio$$uUniversidad de Zaragoza
000165293 245__ $$aFeasibility of electronic brachytherapy in cervix cancer–A dosimetric comparison of different brachytherapy techniques
000165293 260__ $$c2022
000165293 5060_ $$aAccess copy available to the general public$$fUnrestricted
000165293 5203_ $$aIntroducción: This study analyzes cases in which electronic brachytherapy (eBT) led to acceptable treatment plans in cervical cancer. Findings were compared with dosimetry values obtained in 192 Ir-based treatments according to the high-risk clinical target volume (HR-CTV) and the disease stage.
Material and methods: We retrospectively analyzed 48 patients with cervical cancer from two centers. The patients were treated with 192 Ir based on MRI. It was possible to use interstitial needles via an Utrecht-type applicator. Dosimetry was simulated using eBT and the parameters D90 and D98 (HR-CTV) and D2cc, D1cc, and D0.1cc (bladder, rectum, and sigmoid colon) were evaluated. The Mann-Whitney U test was used for comparison. The overall cohort of patients was analyzed, as were the sub-cohorts based on stage (FIGO stages I + IIA, IIB and III–IV). Finally, the dosimetry of the eBT plans was evaluated, and the plans obtained were classified as “good”, “acceptable”, or “poor”.
Results: Statistically significant differences were found between the eBT and 192 Ir plans for D98 (HR-CTV), D1cc and D0.1cc (bladder), and D1cc and D0.1cc (sigmoid colon). A total of 31 cases (64.6%) were considered good, seven (14.6%) were considered acceptable, and 10 (20.8%) were considered poor. For volumes < 30 cc, all the plans were good or acceptable; for volumes > 30 cc, 54.3% were good, and 71.4% were good or acceptable. By stage, eBT plans for patients with stage IB–IIA disease were good in 100%, whereas those for patients with stage IIB were good in 70.6% and III–IV disease were good in 50%.
Conclusions: eBT provides appropriate dosimetry for treatment of cervical cancer in selected cases.
000165293 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000165293 590__ $$a1.9$$b2022
000165293 591__ $$aRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING$$b100 / 135 = 0.741$$c2022$$dQ3$$eT3
000165293 591__ $$aONCOLOGY$$b215 / 241 = 0.892$$c2022$$dQ4$$eT3
000165293 592__ $$a0.741$$b2022
000165293 593__ $$aRadiology, Nuclear Medicine and Imaging$$c2022$$dQ2
000165293 593__ $$aOncology$$c2022$$dQ2
000165293 594__ $$a3.6$$b2022
000165293 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165293 700__ $$aGonzález Pérez, Victor
000165293 700__ $$aPellejero-Pellejero, Santiago
000165293 700__ $$aRodríguez Ruiz, Lucia
000165293 700__ $$aGuinot Rodríguez, José Luis
000165293 700__ $$aVillafranca-Iturre, Elena
000165293 700__ $$aMéndez-Villamón, Agustina$$uUniversidad de Zaragoza
000165293 700__ $$aGandía Martínez, Almudena
000165293 700__ $$aFuentemilla-Urío, Naiara
000165293 700__ $$aRuggeri, Ricardo
000165293 7102_ $$11011$$2770$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Radiol. y Medicina Física
000165293 773__ $$g21, 4 (2022), 389-396$$pBrachytherapy$$tBrachytherapy$$x1538-4721
000165293 8564_ $$s667189$$uhttps://zaguan.unizar.es/record/165293/files/texto_completo.pdf$$yVersión publicada
000165293 8564_ $$s2353681$$uhttps://zaguan.unizar.es/record/165293/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165293 909CO $$ooai:zaguan.unizar.es:165293$$particulos$$pdriver
000165293 951__ $$a2025-12-19-14:44:33
000165293 980__ $$aARTICLE